9.11
-0.54 (-5.60%)
| Previous Close | 9.65 |
| Open | 9.67 |
| Volume | 1,923,973 |
| Avg. Volume (3M) | 2,470,989 |
| Market Cap | 900,307,904 |
| Price / Sales | 9.44 |
| Price / Book | 5.28 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -16.11% |
| Operating Margin (TTM) | -466.29% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 30.33% |
| Current Ratio (MRQ) | 11.00 |
| Operating Cash Flow (TTM) | -20.48 M |
| Levered Free Cash Flow (TTM) | -9.60 M |
| Return on Assets (TTM) | -6.10% |
| Return on Equity (TTM) | -6.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ARS Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.93% |
| % Held by Institutions | 80.28% |
| 52 Weeks Range | ||
| Median | 40.00 (339.08%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth Capital | 04 Sep 2025 | 40.00 (339.08%) | Buy | 10.69 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |